Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.
Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The fireside chat will be held on April 19, 2023, featuring CEO Taylor Schreiber and CFO Andrew Neill, from 2:15 to 2:55 p.m. ET. The discussion will be available via live webcast and archived for 90 days. Shattuck is focused on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, leveraging its proprietary ARC® platform and the SL-172154 program, currently in multiple Phase 1 trials.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
